CA2401067A1 - Procedes de criblage et d'identification de facteurs de virulence pathogene - Google Patents
Procedes de criblage et d'identification de facteurs de virulence pathogene Download PDFInfo
- Publication number
- CA2401067A1 CA2401067A1 CA002401067A CA2401067A CA2401067A1 CA 2401067 A1 CA2401067 A1 CA 2401067A1 CA 002401067 A CA002401067 A CA 002401067A CA 2401067 A CA2401067 A CA 2401067A CA 2401067 A1 CA2401067 A1 CA 2401067A1
- Authority
- CA
- Canada
- Prior art keywords
- nematode
- pathogen
- virulence factor
- marker
- develop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 99
- 238000012216 screening Methods 0.000 title claims abstract description 36
- 230000001717 pathogenic effect Effects 0.000 title claims description 162
- 244000052769 pathogen Species 0.000 title claims description 152
- 230000007923 virulence factor Effects 0.000 title claims description 54
- 239000000304 virulence factor Substances 0.000 title claims description 54
- 241000244206 Nematoda Species 0.000 claims abstract description 136
- 208000037581 Persistent Infection Diseases 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims description 85
- 239000003550 marker Substances 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 35
- 238000012360 testing method Methods 0.000 claims description 31
- 210000000936 intestine Anatomy 0.000 claims description 24
- 230000002147 killing effect Effects 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 19
- 241000607142 Salmonella Species 0.000 claims description 18
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 230000010196 hermaphroditism Effects 0.000 claims description 16
- 230000007918 pathogenicity Effects 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 10
- 230000002085 persistent effect Effects 0.000 claims description 7
- 230000001418 larval effect Effects 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 abstract description 5
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 230000009745 pathological pathway Effects 0.000 abstract description 2
- 239000005090 green fluorescent protein Substances 0.000 description 28
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 27
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 230000001775 anti-pathogenic effect Effects 0.000 description 11
- XCKKIKBIPZJUET-VYKNHSEDSA-N morphine hydrochloride Chemical compound Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XCKKIKBIPZJUET-VYKNHSEDSA-N 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000005923 long-lasting effect Effects 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 101100190323 Caenorhabditis elegans phm-2 gene Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000181693 Pseudomonas aeruginosa PA14 Species 0.000 description 2
- 240000003085 Quassia amara Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- -1 but not limited to Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100108292 Caenorhabditis elegans aex-2 gene Proteins 0.000 description 1
- 101100281516 Caenorhabditis elegans fox-1 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000588731 Hafnia Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000902235 Oides Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940061319 ovide Drugs 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000034958 pharyngeal pumping Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/255—Salmonella (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
- G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des procédés de criblage permettant d'identifier l'action réciproque entre des signaux environnementaux et hôtes ( par exemple des signaux dépendants ou indépendants de l'hôte) et des chemins pathogènes physiologiques qui combattent ou qui régulent les gènes responsables de l'établissement d'une infection persistante, par exemple lors de la colonisation de l'intestin du nématode.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19018600P | 2000-03-17 | 2000-03-17 | |
| US60/190,186 | 2000-03-17 | ||
| PCT/US2001/040311 WO2001071343A1 (fr) | 2000-03-17 | 2001-03-16 | Procedes de criblage et d'identification de facteurs de virulence pathogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2401067A1 true CA2401067A1 (fr) | 2001-09-27 |
Family
ID=22700341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002401067A Abandoned CA2401067A1 (fr) | 2000-03-17 | 2001-03-16 | Procedes de criblage et d'identification de facteurs de virulence pathogene |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1269180A1 (fr) |
| JP (1) | JP2003528318A (fr) |
| AU (1) | AU2001250037A1 (fr) |
| CA (1) | CA2401067A1 (fr) |
| MX (1) | MXPA02009051A (fr) |
| WO (1) | WO2001071343A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002316119A1 (en) * | 2001-05-16 | 2002-11-25 | The General Hospital Corporation | Screening methods for pathogen virulence factors under low oxygen conditions. |
| CN112575055A (zh) * | 2020-12-21 | 2021-03-30 | 广西壮族自治区兽医研究所 | 利用缺陷型秀丽隐杆线虫快速检测牛源志贺菌毒力的方法 |
| CN116326547B (zh) * | 2023-01-06 | 2023-11-10 | 广东省农业科学院植物保护研究所 | 一种针对荔枝蒂蛀虫幼虫室内毒力测定方法 |
-
2001
- 2001-03-16 CA CA002401067A patent/CA2401067A1/fr not_active Abandoned
- 2001-03-16 JP JP2001569479A patent/JP2003528318A/ja not_active Withdrawn
- 2001-03-16 WO PCT/US2001/040311 patent/WO2001071343A1/fr not_active Application Discontinuation
- 2001-03-16 EP EP01923334A patent/EP1269180A1/fr not_active Withdrawn
- 2001-03-16 MX MXPA02009051A patent/MXPA02009051A/es not_active Application Discontinuation
- 2001-03-16 AU AU2001250037A patent/AU2001250037A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02009051A (es) | 2010-06-02 |
| EP1269180A1 (fr) | 2003-01-02 |
| AU2001250037A1 (en) | 2001-10-03 |
| WO2001071343A1 (fr) | 2001-09-27 |
| JP2003528318A (ja) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Powell et al. | Models of Caenorhabditis elegans infection by bacterial and fungal pathogens | |
| Mulcahy et al. | Drosophila melanogaster as an animal model for the study of Pseudomonas aeruginosa biofilm infections in vivo | |
| Apidianakis et al. | Drosophila melanogaster as a model host for studying Pseudomonas aeruginosa infection | |
| Portal-Celhay et al. | Competition and resilience between founder and introduced bacteria in the Caenorhabditis elegans gut | |
| Bellier et al. | Hypoxia and the hypoxic response pathway protect against pore-forming toxins in C. elegans | |
| Haller et al. | Quorum‐sensing regulator RhlR but not its autoinducer RhlI enables Pseudomonas to evade opsonization | |
| Squiban et al. | C. elegans: an all in one model for antimicrobial drug discovery | |
| Muir et al. | Virulence of Leucobacter chromiireducens subsp. solipictus to Caenorhabditis elegans: characterization of a novel host-pathogen interaction | |
| Scott et al. | Intra strain variation of the effects of Gram-negative ESKAPE pathogens on intestinal colonization, host viability, and host response in the model organism Caenorhabditis elegans | |
| Chen et al. | A disease model of muscle necrosis caused by Aeromonas dhakensis infection in Caenorhabditis elegans | |
| US6461854B1 (en) | Methods of screening compounds useful for prevention of infection or pathogenicity | |
| US7078584B2 (en) | Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection | |
| US7166270B1 (en) | Methods of screening compounds useful for prevention of infection or pathogenicity | |
| CA2401067A1 (fr) | Procedes de criblage et d'identification de facteurs de virulence pathogene | |
| US6905670B2 (en) | Methods of screening compounds useful for prevention of infection or pathogenicity | |
| Kitisin et al. | Regulation of DAF-16-mediated longevity and immune response to Candida albicans infection in Caenorhabditis elegans | |
| US20020038463A1 (en) | Methods for screening and identifying host pathogen defense genes | |
| US20050019259A1 (en) | Screening methods for pathogen virulence factors under low oxygen conditions | |
| US7112716B2 (en) | Methods for screening and identifying host pathogen defense genes | |
| Tse-Kang et al. | Activation of intestinal immunity by pathogen effector-triggered aggregation of lysosomal TIR-1/SARM1 | |
| US20010028875A1 (en) | Screening methods for gram-positive enterococcal virulence factors | |
| Fast et al. | Complex symbiont-pathogen interactions inhibit intestinal repair | |
| Gálvez Silva | Relative contribution of the pKpVP plasmid and the GIE492 and ICEKp10 genomic islands to the Klebsiella pneumoniae virulence over the zebrafish host model | |
| Styer | Using genetic analysis and the model organism Caenorhabditis elegans to identify bacterial virulence factors and innate immune defenses against pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |